184 related articles for article (PubMed ID: 32977745)
1. HIV prevention is not all about HIV - using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection.
Vickerman P; Quaife M; Kilbourne-Brook M; Mvundura M; Eakle R; Terris-Prestholt F
BMC Infect Dis; 2020 Sep; 20(1):704. PubMed ID: 32977745
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.
Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P
J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654
[TBL] [Abstract][Full Text] [Related]
3. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa.
Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Kilbourne-Brook M; Mvundura M; Delany-Moretlwe S; Terris-Prestholt F
Med Decis Making; 2018 Jan; 38(1):120-133. PubMed ID: 28863752
[TBL] [Abstract][Full Text] [Related]
4. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).
Ngure K; Friedland BA; Szydlo DW; Roberts ST; Garcia M; Levy L; Akello CA; Reddy K; Palanee-Phillips T; Macdonald P; Siziba B; Soto-Torres L; Hosek S; Hillier SL; Nair G; Celum C; van der Straten A
PLoS One; 2023; 18(6):e0287525. PubMed ID: 37352296
[TBL] [Abstract][Full Text] [Related]
5. Preferences for Long-Acting PrEP Products Among Women and Girls: A Quantitative Survey and Discrete Choice Experiment in Eswatini, Kenya, and South Africa.
Little KM; Hanif H; Anderson SM; Clark MR; Gustafson K; Doncel GF
AIDS Behav; 2024 Mar; 28(3):936-950. PubMed ID: 37971614
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
7. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.
Minnis AM; Browne EN; Boeri M; Agot K; van der Straten A; Ahmed K; Weinrib R; Mansfield C
J Acquir Immune Defic Syndr; 2019 Apr; 80(4):394-403. PubMed ID: 30633040
[TBL] [Abstract][Full Text] [Related]
8. Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment.
Quaife M; Eakle R; Cabrera M; Vickerman P; Tsepe M; Cianci F; Delany-Moretlwe S; Terris-Prestholt F
BMJ Open; 2016 Jun; 6(6):e010682. PubMed ID: 27354071
[TBL] [Abstract][Full Text] [Related]
9. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study.
van der Straten A; Ryan JH; Reddy K; Etima J; Taulo F; Mutero P; Taylor J; Piper J; Musara P;
J Int AIDS Soc; 2020 Jun; 23(6):e25536. PubMed ID: 32524700
[TBL] [Abstract][Full Text] [Related]
10. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.
Mack N; Evens EM; Tolley EE; Brelsford K; Mackenzie C; Milford C; Smit JA; Kimani J
J Int AIDS Soc; 2014; 17(3 Suppl 2):19157. PubMed ID: 25224616
[TBL] [Abstract][Full Text] [Related]
11. HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa.
Little KM; Flomen L; Hanif H; Anderson SM; Thurman AR; Clark MR; Doncel GF
AIDS Behav; 2022 Sep; 26(9):3099-3109. PubMed ID: 35360893
[TBL] [Abstract][Full Text] [Related]
12. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG
BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697
[TBL] [Abstract][Full Text] [Related]
13. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
[TBL] [Abstract][Full Text] [Related]
14. Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment.
Minnis AM; Atujuna M; Browne EN; Ndwayana S; Hartmann M; Sindelo S; Ngcwayi N; Boeri M; Mansfield C; Bekker LG; Montgomery ET
J Int AIDS Soc; 2020 Jun; 23(6):e25528. PubMed ID: 32544303
[TBL] [Abstract][Full Text] [Related]
15. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe.
Friedland BA; Mgodi NM; Palanee-Phillips T; Mathur S; Plagianos MG; Bruce IV; Lansiaux M; Murombedzi C; Musara P; Dandadzi A; Reddy K; Ndlovu N; Zulu SK; Shale LR; Zieman B; Haddad LB
BMJ Open; 2024 Mar; 14(3):e075381. PubMed ID: 38479746
[TBL] [Abstract][Full Text] [Related]
16. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
17. Acceptability and Predictors of Uptake of Anti-retroviral Pre-exposure Prophylaxis (PrEP) Among Fishing Communities in Uganda: A Cross-Sectional Discrete Choice Experiment Survey.
Kuteesa MO; Quaife M; Biraro S; Katumba KR; Seeley J; Kamali A; Nakanjako D
AIDS Behav; 2019 Oct; 23(10):2674-2686. PubMed ID: 30734882
[TBL] [Abstract][Full Text] [Related]
18. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
[TBL] [Abstract][Full Text] [Related]
19. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.
Mayanja Y; Kamacooko O; Lunkuse JF; Muturi-Kioi V; Buzibye A; Omali D; Chinyenze K; Kuteesa M; Kaleebu P; Price MA
J Int AIDS Soc; 2022 May; 25(5):e25909. PubMed ID: 35543110
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
